Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study

Hamerlynck JV, J V Hamerlynck, A P Maskens, Maskens AP, C Mangioni, Mangioni C, van der Burg ME, M E van der Burg, Wils JA, J A Wils, J. B. Vermorken, Vermorken JB, N Rotmensz, Rotmensz N
Gynecologic Oncology · 1985 · doi:10.1016/0090-8258(85)90045-9 · PMID:2998957
other OA: closed public-domain-us
View on PubMed View at publisher

Abstract

Progestin therapy of ovarian carcinoma in the past has been reported to lead to varying response rates. A multicenter phase II study of high-dose MPA was conducted in 53 patients with epithelial ovarian cancer who had received adequate trials of conventional therapy with cytotoxic agents. Forty-one patients were included for response and toxicity evaluations. Only one partial response has been recorded with a duration of 20 weeks. Stabilization of disease was observed in 7 patients. The present investigation shows that MPA given at the present high dose is not effective in patients extensively pretreated with chemotherapy.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Medroxyprogesterone Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma, Mucinous Adenocarcinoma, Mucinous Adult Aged Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols Carcinoma Carcinoma Drug Evaluation Drug Resistance Endometriosis Endometriosis Female Humans Medroxyprogesterone Medroxyprogesterone

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (1)

Cited by (1)

Source provenance

europepmc
last seen: 2026-08-30T09:23:35.175841+00:00
pubmed
last seen: 2026-05-13T22:09:40.384591+00:00
unpaywall
last seen: 2026-09-01T06:29:04.589233+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine